INO Valuation

Inovio Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

2.310

+0.13(5.963%)1D

Overview
Forecast
Valuation
Earnings

INO Relative Valuation

INO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, INO is overvalued; if below, it's undervalued.

Historical Valuation

Inovio Pharmaceuticals Inc (INO) is now in the Fair zone, suggesting that its current forward PS ratio of 1158.51 is considered Fairly compared with the five-year average of -3.83. The fair price of Inovio Pharmaceuticals Inc (INO) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：2.18

Fair

-1.32

Trailing

Forward

0.00

EV/EBITDA

Inovio Pharmaceuticals Inc. (INO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.73. The thresholds are as follows: Strongly Undervalued below -7.51, Undervalued between -7.51 and -4.62, Fairly Valued between 1.16 and -4.62, Overvalued between 1.16 and 4.05, and Strongly Overvalued above 4.05. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.84

EV/EBIT

Inovio Pharmaceuticals Inc. (INO) has a current EV/EBIT of -0.84. The 5-year average EV/EBIT is -2.23. The thresholds are as follows: Strongly Undervalued below -9.12, Undervalued between -9.12 and -5.67, Fairly Valued between 1.22 and -5.67, Overvalued between 1.22 and 4.66, and Strongly Overvalued above 4.66. The current Forward EV/EBIT of -0.84 falls within the Historic Trend Line -Fairly Valued range.

1158.51

Inovio Pharmaceuticals Inc. (INO) has a current PS of 1158.51. The 5-year average PS is 398.49. The thresholds are as follows: Strongly Undervalued below -520.45, Undervalued between -520.45 and -60.98, Fairly Valued between 857.96 and -60.98, Overvalued between 857.96 and 1317.43, and Strongly Overvalued above 1317.43. The current Forward PS of 1158.51 falls within the Overvalued range.

0.00

P/OCF

Inovio Pharmaceuticals Inc. (INO) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.95. The thresholds are as follows: Strongly Undervalued below -9.75, Undervalued between -9.75 and -6.35, Fairly Valued between 0.45 and -6.35, Overvalued between 0.45 and 3.85, and Strongly Overvalued above 3.85. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.30

P/FCF

Inovio Pharmaceuticals Inc. (INO) has a current P/FCF of -1.30. The 5-year average P/FCF is -1.98. The thresholds are as follows: Strongly Undervalued below -6.76, Undervalued between -6.76 and -4.37, Fairly Valued between 0.42 and -4.37, Overvalued between 0.42 and 2.81, and Strongly Overvalued above 2.81. The current Forward P/FCF of -1.30 falls within the Historic Trend Line -Fairly Valued range.

Inovio Pharmaceuticals Inc (INO) has a current Price-to-Book (P/B) ratio of 2.81. Compared to its 3-year average P/B ratio of 1.50 , the current P/B ratio is approximately 87.42% higher. Relative to its 5-year average P/B ratio of 2.23, the current P/B ratio is about 25.73% higher. Inovio Pharmaceuticals Inc (INO) has a Forward Free Cash Flow (FCF) yield of approximately -81.90%. Compared to its 3-year average FCF yield of -97.59%, the current FCF yield is approximately -16.08% lower. Relative to its 5-year average FCF yield of -66.62% , the current FCF yield is about 22.93% lower.

2.81

P/B

Median3y

1.50

Median5y

2.23

-81.90

FCF Yield

Median3y

-97.59

Median5y

-66.62

Competitors Valuation Multiple

The average P/S ratio for INO's competitors is 214.45, providing a benchmark for relative valuation. Inovio Pharmaceuticals Inc Corp (INO) exhibits a P/S ratio of 1158.51, which is 440.23% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

INO.O

Inovio Pharmaceuticals Inc

Protara Therapeutics Inc

Loss

123.85M

CRBP.O

Corbus Pharmaceuticals Holdings Inc

128.17

142.41M

IKT.O

Inhibikase Therapeutics Inc

Loss

114.76M

Performance Decomposition

Market capitalization of INO decreased by 62.28% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -31.99K to -66.13K.

The secondary factor is the P/E Change, contributed -68.99%to the performance.

Overall, the performance of INO in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-100.00%

100.76K → 0.00

Revenue Growth

106.71%

-31.99K → -66.13K

Margin Expansion

-68.99%

-2.88 → -0.89

P/E Change

-62.28%